Emvena launches with PxB Fund investment to develop preeclampsia treatment
AI Summary- Emvena Therapeutics launched to develop a treatment targeting the biological causes of preeclampsia.
- Preeclampsia affects 2% to 8% of pregnancies globally, according to the company.
- Emvena plans to advance its placenta-targeted technology toward clinical development after mouse studies.